Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Cells · 15.02.2025 · 14 (4) · 290
DOI: 10.3390/cells14040290 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 15.02.2025. Verfasst von Margery Gang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Fellowship Program, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH/NHLBI, NHLBI NIH HHS, NIH/National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Allogeneic hematopoietic cell transplantation (HCT) remains an important curative-intent treatment for many patients with acute myeloid leukemia (AML), but AML recurrence after allografting is common. Many factors associated with relapse after allogeneic HCT have been identified over the years. Central among these is measurable (“minimal”) residual disease (MRD) as detected by multiparameter flow cytometry, quantitative polymerase chain reaction, and/or next-generation sequencing. Demonstration of a strong, independent prognostic role of pre- and early post-HCT MRD has raised hopes MRD could also serve as a predictive biomarker to inform treatment decision-making, with emerging data indicating the potential value to guide candidacy assessment for allografting as a post-remission treatment strategy, the selection of conditioning intensity, use of small molecule inhibitors as post-HCT maintenance therapy, and preemptive infusion of donor lymphocytes. Monitoring for leukemia recurrence after HCT and surrogacy for treatment response are other considerations for the clinical use of MRD data. In this review, we will outline the current landscape of MRD as a biomarker for patients with AML undergoing HCT and discuss areas of uncertainty and ongoing research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology and Oncology Fellowship Program, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA.
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
ORCID-Profile: Margery Gang, Megan Othus, Roland B Walter
Förderung
- NIH/NHLBI
- NHLBI NIH HHS
- NIH/National Heart, Lung, and Blood Institute
- José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research
Zitieren
APA
Gang, M., Othus, M., & Walter, R. B. (2025). Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Cells, 14(4), 290. https://doi.org/10.3390/cells14040290
Vancouver
Gang M, Othus M, Walter RB. Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Cells. 2025;14(4):290. doi:10.3390/cells14040290
BibTeX
@article{Gang2025,
author = {Gang, Margery and Othus, Megan and Walter, Roland B},
title = {Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia},
journal = {Cells},
year = {2025},
volume = {14},
number = {4},
pages = {290},
doi = {10.3390/cells14040290}
}
EUVIMED